Try
Travere Therapeutics Inc. Common Stock
TVTXUnited States
62 filed reports · 674 financial concepts · 0 earnings calls · 1 media appearances
Filed reports
62 reports · Jun 2015 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 33 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 33 | 5,781 | Jun 2015 to Jun 2026 |
| Current · 8-KSEC EDGAR | 17 | 33 | Jun 2015 to Mar 2021 |
| Annual · 10-KSEC EDGAR | 10 | 5,247 | Dec 2015 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 496 | Dec 2017 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 143 | Mar 2018 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 419 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 262 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 19, 2026 | 907 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 295 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 180 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 185 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 21, 2025 | 512 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 31, 2024 | 194 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 177 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 6, 2024 | 190 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 20, 2024 | 541 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 175 | Open |
Financial data
674 concepts · 11,700 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial653 concepts · 11,231 facts · Jan 2013 to Jul 2026
- Corporate debt securities189 · Dec 2017 to Jun 2026
- Research and development67 · Dec 2014 to Jun 2026
- Selling, general and administrative67 · Dec 2014 to Jun 2026
- Income tax expense benefit63 · Dec 2013 to Jun 2026
- Net income loss63 · Dec 2013 to Jun 2026
- Operating income loss63 · Dec 2013 to Jun 2026
- Other nonoperating income expense63 · Dec 2013 to Jun 2026
- Cash and cash equivalents at carrying value62 · Dec 2013 to Jun 2026
- Revenue62 · Dec 2013 to Jun 2026
- Allocated share based compensation expense61 · Dec 2013 to Jun 2026
- Amortization of intangible assets61 · Dec 2013 to Jun 2026
- Comprehensive income net of tax61 · Dec 2013 to Jun 2026
- Nonoperating income expense61 · Dec 2013 to Jun 2026
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent61 · Dec 2013 to Jun 2026
- Selling general and administrative expense61 · Dec 2013 to Jun 2026
- Depreciation depletion and amortization60 · Dec 2013 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest60 · Dec 2013 to Jun 2026
- Increase decrease in accounts receivable60 · Dec 2013 to Jun 2026
- Increase decrease in inventories60 · Dec 2013 to Jun 2026
- Payment of guaranteed minimum royalty60 · Dec 2013 to Jun 2026
- Payments to acquire intangible assets60 · Dec 2013 to Jun 2026
- Proceeds from stock options exercised60 · Dec 2013 to Jun 2026
- Share based compensation60 · Dec 2013 to Jun 2026
- Stockholders equity (US GAAP)59 · Dec 2013 to Jun 2026
Product6 concepts · 270 facts · Dec 2015 to Jun 2026
- Revenue207 · Dec 2015 to Jun 2026
- Cost of goods and services sold (US GAAP)48 · Dec 2021 to Jun 2026
- Contract with customer liability revenue recognized11 · Dec 2021 to Dec 2025
- Inventory write down2 · Dec 2023 to Dec 2024
- Research and development expense1 · Dec 2023
- Revenue (excluding assessed tax)1 · Dec 2020
Segment13 concepts · 166 facts · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Nonoperating income expense14 · Dec 2022 to Jun 2026
- Other research and development expense14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Research and development expense excluding acquired in process cost14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Income loss from discontinued operations net of tax attributable to reporting entity12 · Dec 2022 to Jun 2026
- In-process research and development12 · Dec 2022 to Dec 2025
- Restructuring charges12 · Dec 2022 to Dec 2025
- Royalty expense4 · Mar 2025 to Jun 2026
Guidance2 concepts · 33 facts · Aug 2015 to May 2021
- Revenue Guidance26 · Aug 2015 to Jul 2018
- Revenue Growth Guidance7 · Feb 2020 to May 2021
Segments
436 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis13 members · 256 facts
- License59 · Dec 2019 to Jun 2026
- Product52 · Dec 2019 to Jun 2026
- Tiopronin Products46 · Sep 2018 to Jun 2026
- Bile Acid Products37 · Dec 2016 to Jun 2023
- FILSPARI28 · Dec 2021 to Jun 2026
- Thiola License12 · Dec 2016 to Dec 2019
- Active Pharmaceutical Ingredient5 · Mar 2023 to Dec 2023
- Clinical Development Activity5 · Mar 2023 to Dec 2023
- License And Collaboration Revenue4 · Dec 2021 to Dec 2024
- Kolbam3 · Mar 2022 to Sep 2022
- Collaboration Revenue2 · Dec 2021 to Dec 2022
- License Revenue2 · Dec 2021 to Dec 2022
- Kolbam1 · Dec 2020
Statement business segments1 member · 166 facts
- Reportable166 · Dec 2022 to Jun 2026
Product or serviceus-gaap:ProductOrServiceAxis2 members · 14 facts
- Bile Acid Products7 · Dec 2015 to Jun 2018
- Thiola License7 · Dec 2015 to Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary106 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary159 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes21 claims from 1 reports · Dec 2025
- Risk factors121 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
1 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances1 · Oct 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.